The anticoagulant rivaroxaban should be considered for preventive use in patients with acute coronary syndrome, according to a recommendation from the EU's Committee for Medicinal Products for Human Use. The panel's opinion comes weeks after the FDA sought additional information instead of approving a similar indication in the U.S.

Related Summaries